Clinical Trials Logo

Filter by:
NCT ID: NCT02997722 Terminated - Suicidal Ideation Clinical Trials

The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.

Start date: March 2, 2017
Phase: Phase 4
Study type: Interventional

This study will evaluate the effect of ketamine on the treatment of patients hospitalized with suicidal thoughts. Half of the patients will receive one dose of ketamine in the vein. The other half will receive a placebo. Because we think that ketamine will improve depression and suicidal thoughts, we expect that patients who receive ketamine will require less time in the hospital than patients who receive placebo.

NCT ID: NCT02997540 Terminated - Breast Diseases Clinical Trials

Effect of Body Position and Probe Position on the Localization of Breast Mass

Start date: November 2016
Phase:
Study type: Observational

The purpose of this study is to demonstrate that BVN G-1000 can precisely and consistently measure the position of female breast lesions regardless of patient rotation and probe angle during ultrasound examination.

NCT ID: NCT02997189 Terminated - Clinical trials for Cisplatin Induced Hearing Loss

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

Start date: November 15, 2016
Phase: Phase 2
Study type: Interventional

This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of cancer.

NCT ID: NCT02996448 Terminated - Clinical trials for Autosomal-dominant Hyper-IgE Syndrome

Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome

Start date: November 17, 2016
Phase: Phase 2
Study type: Interventional

Background: AD-HIES is a disease that weakens the immune system. It puts people at risk for infections, particularly Staph and Candida infections. Researchers want to test a vaccine that may help keep people from getting these infections, which would help people with AD-HIES. Objective: To test the new vaccine NDV-3A for protection against infection from the yeast Candida and the bacterium Staphylococcus aureus (Staph). Eligibility: Adults ages 18-55 who have AD-HIES Healthy volunteers ages 18-55 Design: Participants will have 6-7 study visits over 6-7 months. They will also be contacted by phone in between some visits. Participants will be screened with a medical history, physical exam, and blood and urine tests. Participants will have 2 baseline visits. They will have repeat the screening tests. They will have samples of saliva, stool, skin, mucus (oral, nasal, and/or vaginal) collected. Vaginal and stool samples are optional. Any eczema on their skin will be looked at. Participants will fill out symptom diary cards to record how they feel. Participants will have the NDV-3A vaccine injected into a muscle in the arm. Participants will return the next 2 days. They will have a physical exam. Blood will be collected. Participants will have 2 more follow-up visits at the NIH. They will have a physical exam. They will have blood, saliva, stool, skin, vaginal fluid, and/or mucus samples collected. Vaginal and stool samples are optional. Participants will be called once a month for 5 months after the vaccination. There is an optional visit about 6 weeks after the vaccination. Participants will provide a blood sample at this visit.

NCT ID: NCT02996266 Terminated - Ischemic Stroke Clinical Trials

Impact of Fever Prevention in Brain Injured Patients

INTREPID
Start date: January 2017
Phase: N/A
Study type: Interventional

This study will assess the impact of fever prevention on fever burden and short- and long-term neurologic outcomes in brain injured patients. Half of the subjects will undergo fever prevention using a targeted temperature management system and half of the subjects will be treated for fever should it develop.

NCT ID: NCT02995967 Terminated - Overactive Bladder Clinical Trials

Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder

HydrA
Start date: November 2016
Phase: N/A
Study type: Interventional

The specific aim of this trial is to determine if hydrodistention at the time of intradetrusor injection of botulinum toxin A has additional benefit in patients with refractory overactive bladder (OAB) and urgency symptoms compared to intradetrusor injection of botulinum toxin A alone. Consented patients will be randomized to hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A (hydrodistention group) or intradetrusor injection of 100 units of botulinum toxin A alone (botulinum toxin A alone group). The primary aim will be subjective improvement measured as change from baseline at 12 weeks using the OAB-q bother subscale.

NCT ID: NCT02995746 Terminated - Macular Edema Clinical Trials

Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane

DEMO
Start date: January 28, 2016
Phase: N/A
Study type: Interventional

This study seeks to evaluate the effect of the intravitreal 0.7mg dexamethasone implant on central macular thickness and visual acuity in those patients with persistent macular edema after pars plana vitrectomy for epiretinal membrane.

NCT ID: NCT02995330 Terminated - Prostate Cancer Clinical Trials

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Start date: February 9, 2017
Phase: Phase 1
Study type: Interventional

Men with progressive metastatic Castration-Resistant Prostate Cancer post first-line treatment with either androgen deprivation therapy alone or androgen deprivation therapy plus docetaxel who have an identified related female donor (mother sister, daughter, second degree relative such as granddaughter or niece) will undergo bone marrow transplantation followed by post-transplant Cytoxan (PT/Cy) and testosterone.

NCT ID: NCT02995044 Terminated - Sunscreening Agents Clinical Trials

Sun Protection Factor Assay (319/2016)

SPF Assay
Start date: January 4, 2017
Phase: N/A
Study type: Interventional

To evaluate the Sun Protection Factor efficacy on human skin.

NCT ID: NCT02995031 Terminated - Sunscreening Agents Clinical Trials

Sun Protection Factor Assay (318/2016)

SPF Assay
Start date: January 3, 2017
Phase: N/A
Study type: Interventional

To evaluate the Sun Protection Factor efficacy on human skin.